Research on the NASDAQ Stock Market: BLUE Stock In a letter to investors distributed on Monday, September 19, William Blair research analysts updated their forecasts for Bluebird Bio, Inc.’s earnings per share (EPS) in the first quarter of 2023 in a letter to investors. R. Prasad, an analyst at William Blair, has revised his earlier forecast of the quarterly earnings per share for the biotechnology company, bringing it from $0.82 to $0.70. This brings R. Prasad’s total earnings per share forecast for the biotechnology industry to $1.20. According to the average prediction, Bluebird Bio’s earnings for the entire year of the current fiscal year are expected to come in at $4.66 per share. In addition, William Blair anticipated that Bluebird Bio’s earnings for the second quarter of 2023 would be $0.67 per share, earnings for the third quarter of 2023 would be $0.64 per share, earnings for the fourth quarter of 2023 would be $0.63 per share, and earnings for the full year of 2023 would be $0.66 per share.
On Thursday, August 4, Bluebird Bio (NASDAQ: BLUE) announced the results of its most recent quarterly financial report to the public.
The biotechnology company announced earnings per share (EPS) for the quarter of $1.29, which was $0.02 more than the average projection set by analysts, which came in at $1.31. The company also beat the average expectation by $0.02. The total tally for sales achieved over the period was $1.52 million, far lower than the average projection of $6.47 million for the amount that would be achieved. The net margin and the return on equity for Bluebird Bio were in red. The net margin was -2141.34 percent, and the return on equity was -130.19 percent. On Thursday, the shares of Bluebird Bio were placed on the market with an asking price of $6.17 per share. In the most recent 50 trading days, the company’s simple moving average was $5.78, while the average for the most recent 200 trading days was $4.73. The price of a single share of Bluebird Bio has been as low as $2.87 over the past 52 weeks, while the share price has reached a 52-week high of $25.39. Recently, a number of other stock research professionals have revealed their conclusions about the firm they have been looking at. In a research note released on Tuesday, Raymond James indicated that it had increased its price objective for Bluebird Bio from $8.00 to $10.00 and rated the company as having an “outperform” status.
In a research report published on Thursday, August 18, SVB Leerink rated the business as “market perform” and increased their price objective for Bluebird Bio from $8.00 to $10.00. The report also stated that they were increasing their price target for the company. In addition, the company was given a “market perform” rating in the study. Barclays raised their rating of the company from “underweight” to “equal weight” and increased their price target from $3 to $5 in a research note published on August 5. The price objective that The Goldman Sachs Group has set for Bluebird Bio has been raised from $2.00 to $3.00, and the company has been given a “sell” rating in a research report published on Friday, August 19. Three of the equity research analysts have provided the stock with a recommendation to sell, nine of the analysts have provided the stock with a recommendation to hold, and two of the experts have provided the stock with a recommendation to buy. Bloomberg says that the company has an overall rating of “Hold,” and the price target has been set at $10.25.
Over the past few months, several hedge funds have increased the percentage of the company’s shares they possess to a greater extent. In the second quarter, Inspire Investing LLC completed a 3.6% expansion in the amount of bluebird bio stock it possesses in the enterprise. After purchasing an additional 1,773 shares during the most recent quarter, Inspire Investing LLC now has 50,497 shares in the biopharmaceutical business. The value of Inspire Investing LLC’s holdings in the biotechnology company is now $209,000. In addition, the interests of Bluebird Bio, owned by the Teacher Retirement System of Texas, were boosted by 18.5% during the fourth quarter of 2018. The Teacher Retirement System of Texas now has 12,817 shares of the biotechnology business following the purchase of an additional 2,004 shares during the quarter.
The value of the Teacher Retirement System’s 12,817 shares comes to a total of $128,000. In the last three months of 2018, Parametrica Management Ltd. boosted the number of bluebird bio shares it owned, bringing its total ownership percentage to 88.7%. Following the acquisition of a further 3,226 shares during the period under review, Parametrica Management Ltd now holds 40,145 shares of the biotechnology firm’s stock. This gives the company a market value of $401,000. In the final quarter of 2018, Advisor Group Holdings Inc. boosted the amount of Bluebird Bio stock owned by 24.4%. Advisor Group Holdings Inc. now has 18,058 shares of the biotechnology company’s stock, which are currently valued at $180,000 after purchasing an additional 3,543 shares during the quarter.
Last but not least, during the first three months of this year, US Bancorp DE increased the percentage of Bluebird Bio shares it owned by an impressive 82.9%. US Bancorp DE now holds 8,486 shares in the biotechnology business, valued at $41,000, thanks to purchasing an additional 3,847 shares during the quarter. US Bancorp DE’s entire investment in the company is valued at $70,000. In addition, 78.25 hedge funds and other institutional investors own the company’s stock.
On Friday, August 19, a business insider named Jason Cole sold 14,194 shares of the firm’s stock. This is just one of the latest occurrences relating to this topic. The number of sold shares resulted in a total sales volume of $78,492.82, and the average price per share received was $5.53. After the conclusion of the transaction, the business insider now directly owns 189,546 shares of the company’s stock. The current stock price of around $1,048,189.38 gives the business insider a total value of approximately $1,048,189.38. By releasing a legal document, which may be seen on the SEC website, the Securities and Exchange Commission (SEC) disclosed the transaction to the public. In other items about the company, on August 4, its Chief Executive Officer, Andrew Obenshain, successfully concluded a transaction in which he sold 21,805 shares of the company’s stock. Earnings of $95,723.95 were realized as a direct consequence of the sale of the shares, which were transacted at an average price of $4.39 per share. The company’s Chief Executive Officer (CEO) now holds a direct ownership stake in 247,131 company shares, which are currently valued at about $1,084,905.09 each. The Securities and Exchange Commission has submitted legal papers relating to the transaction. Readers interested in obtaining a copy of this paperwork can follow the link in the preceding line.
Additionally, on Friday, August 19, an insider of the firm named Jason Cole sold 14,194 shares of the company’s stock. The number of sold shares resulted in a total sales volume of $78,492.82, and the average price per share received was $5.53. Following the transaction, the corporate insider now owns a total of 189,546 shares of the business, which have an aggregate value of $1,048,189.38. The disclosure about the purchase can be seen in this particular location. The company’s insiders have sold 44,805 company stock over the most recent three months, resulting in a total sale price of $213,636 being realized by them. Insiders hold ownership of 2.90 percent of the company’s shares.